The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects

BACKGROUND: Fabry disease is a rare inherited glycosphingolipid storage disorder caused by deleterious mutations in the GLA gene coding for the lysosomal enzyme α-galactosidase A. The glucosylceramide synthase inhibitor lucerastat is an iminosugar with potential to provide oral substrate reduction t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Markus S., Sidharta, Patricia N., Voors-Pette, Christine, Darpo, Borje, Xue, Hongqi, Dingemanse, Jasper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590462/
https://www.ncbi.nlm.nih.gov/pubmed/33109218
http://dx.doi.org/10.1186/s13023-020-01582-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590462/
https://www.ncbi.nlm.nih.gov/pubmed/33109218
http://dx.doi.org/10.1186/s13023-020-01582-7

Ejemplares similares